All In Biotech

Free tool

FAERS Monitor: Rezdiffra

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 217785 or its brand name (Rezdiffra, Resmetirom). Reports on generic versions are filed under their own applications.

Reports

2,298

Serious

834

36% of reports

Hospitalization

184

Death reported

125

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • diarrhoea368
  • nausea320
  • pruritus301
  • hepatic cirrhosis175
  • fatigue169
  • alanine aminotransferase increased161
  • aspartate aminotransferase increased149
  • abdominal pain upper138
  • weight decreased131
  • dizziness125
  • vomiting117
  • abdominal pain103
  • constipation102
  • disease progression95
  • hepatic enzyme increased90

Reports by year received

View as table
YearReports
20201
20211
20221
2024285
2025929
20261,081

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,861 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hepatic cirrhosisSignal17586.174.614,506
aspartate aminotransferase increasedSignal14925.722.03,518
alanine aminotransferase increasedSignal16124.120.73,537
hepatic enzyme increasedSignal9012.19.9907
disease progressionSignal957.46.0518
pruritusSignal3017.26.51,621
abdominal pain upperSignal1386.15.2594
diarrhoeaSignal3685.24.81,290
weight decreasedSignal1314.33.6332
constipationSignal1024.33.5256
abdominal painSignal1034.13.4236
nauseaSignal3203.73.3653
dizzinessSignal1252.31.992
vomitingSignal1172.31.984
fatigue1692.01.785

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.